As excipients are used: the water purified starch prezhelatinizirovanny, cellulose microcrystallic, кросповидон, lactoses monohydrate, magnesium stearate. The cover is made from: opadry white (OY-S-9603) with dye – titanium dioxide (E171).

Pharmacological effect of drug Teveten

The blocker of receptors of angiotensin, has hypotensive, vazodilatiruyushchy effect.

Pharmacodynamics

Has selective effect on angiotenzinovy receptors in kidneys and bark of adrenal glands. Forms with receptors strong communication, with further slow dissociation. Eprosartan prevents development or reduces effect of angiotensin II.

Reduces: arterial vasoconstriction, pressure of a small circle of blood circulation, general peripheric vascular resistance, secretion of Aldosteronum.

Prolonged use of Teveten suppresses proliferative effect of angiotensin II on cells of unstriated muscles of a myocardium and vessels. The anti-hypertensive effect remains for 24 hours, excepting development of orthostatic arterial hypotension after reception of the first dose. At regular reception, after 2-3 weeks there occurs stabilization of anti-hypertensive effect.

Influence of an eprosartan on the level of concentration of triglycerides at patients with arterial hypertension is noted. Teveten accepted on an empty stomach does not exert impact on glucose level in blood, does not affect purine exchange and does not exert considerable impact on removal of uric acid. Interruption of reception of Teveten is not followed by signs of "withdrawal".

Pharmacokinetics

Bioavailability after one-time reception of 300 mg of drug makes 13%.

Eprosartan has a high svyazyvayemost with proteins of a blood plasma – 98%, at the same time the level of a svyazyvayemost does not depend on age, sex or function of a liver of the patient. Level of a svyazyvayemost does not change at not strongly expressed or average level of a renal failure, however can decrease at its severe forms.

The maximum level of concentration in blood of drug is reached after 1-2 h from the moment of reception. Reception with food lowers absorption for 25%. The elimination half-life makes 5-9 hours.

About 90% and 7% with urine are removed generally with a stake. About 2% are removed through kidneys in the form of glucuronides. As well as its analogs, Teveten almost does not kumulirut in an organism. A floor, weight, race of the patient do not influence Teveten's pharmacokinetics. The drug pharmacokinetics at persons is younger than 18 years was not studied.

Indications to use

Teveten is shown at arterial hypertension.

Drug Teveten is contraindicated

at individual intolerance of active ingredient or other components of drug;
to pregnant women;
at a lactation;
to the patients who did not reach 18 years;
at a lactose intolerance or a syndrome of a glyukozo-galaktoznoymalyabsorbtion.

It is taken with caution at: severe forms of chronic heart failure, bilateral stenosis of renal arteries, renal failure (KK less than 60 ml/min.).

Administration of drug at pregnancy and in the period of a lactation

According to the instruction Teveten is not recommended for inclusion in pregnancy time. At pregnancy establishment administration of drug has to be stopped at once. If there is a requirement in therapy continuations, transition to Teveten's analogs or alternative anti-hypertensive drugs which admissibility of reception at pregnancy was established is necessary. Teveten's reception on the 2nd and 3rd trimester of pregnancy exerts toxic impact on a fruit - worsening function of kidneys, leads to a delay of ossification of bones of a skull. Newborns whose mothers during pregnancy accepted Teveten have to undergo inspection on existence of arterial hypotension. Теветен в упаковке

Data on penetration of drug into milk were not received. In need of performing therapy by Teveten, breastfeeding has to be stopped.

Dosage and routes of administration

Is accepted orally, in independence of meal. The daily dose recommended by Teveten's instruction makes on 1 tablet (735,8 mg) one-time reception in the morning. Maximum daily dose of 1200 mg.

Practical reviews of Teveten of therapy showed that for patients of advanced age and to persons with abnormal liver functions dose adjustment is not required. For patients with a renal failure the maximum admissible daily dose makes 600 mg. Prolonged use of Teveten is admissible.

Side effects

From the recorded reviews of Teveten of therapy, side effects are most often shown in a look:

adynamy;
headache;
dizzinesses;
the expressed falling of arterial pressure;
allergic skin reactions;
Quincke's diseases;
complaints to a condition of the alimentary system (nausea, diarrhea, vomiting);
renal failures.

Overdose

About Teveten's overdose limited data are obtained. The expressed lowering of arterial pressure can become a symptom of overdose. As treatment symptomatic therapy is recommended.

Interaction with other medicines

Teveten does not exert impact on pharmacokinetics of warfarin, digoxin and Glibenclamidum. In turn do not exert impact on Teveten's pharmacokinetics флуконазол, кетоконазол and ranitidine.

Teveten's combination to thiazide diuretics and blockers of calcium channels is allowed, at the same time mutual strengthening of hypotensive effect is noted. Teveten's instruction allows its use together with hypolipidemic drugs, including: правастатин, ловастатин, gemfibrozit, симвастатин, фенофибрат.

Special instructions

As well as in a case with the majority of analogs of Teveten, patients with a reduced volume of the circulating blood prior to treatment by drug need to carry out correction of OTsK.

Patients with a renal failure, before appointment and in the course of therapy, need to control function of kidneys. At deterioration in renal activity the attending physician has to reconsider need of continuation of treatment.

Comments that Teveten negatively affects ability of driving of motor transport were not received. Due to possible dizziness it is recommended to be careful at control of vehicles and at other potentially dangerous types of activity.